메뉴 건너뛰기




Volumn 30, Issue 3, 2014, Pages 219-230

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study

Author keywords

Incident cancer; Mortality; Osteprotegerin

Indexed keywords

BIOLOGICAL MARKER; OSTEOPROTEGERIN;

EID: 84930898101     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-014-9975-3     Document Type: Article
Times cited : (26)

References (33)
  • 1
    • 0032584208 scopus 로고    scopus 로고
    • Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
    • COI: 1:CAS:528:DyaK1cXitlKjsLY%3D, PID: 9520411
    • Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS. 1998;95(7):3597–602.
    • (1998) PNAS , vol.95 , Issue.7 , pp. 3597-3602
    • Yasuda, H.1    Shima, N.2    Nakagawa, N.3
  • 2
    • 7344233085 scopus 로고    scopus 로고
    • Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
    • COI: 1:CAS:528:DyaK1cXjs1Oru70%3D, PID: 9603945
    • Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363–7.
    • (1998) J Biol Chem , vol.273 , Issue.23 , pp. 14363-14367
    • Emery, J.G.1    McDonnell, P.2    Burke, M.B.3
  • 3
    • 0031005576 scopus 로고    scopus 로고
    • Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
    • COI: 1:CAS:528:DyaK2sXislCgtLc%3D, PID: 9108485
    • Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.
    • (1997) Cell , vol.89 , Issue.2 , pp. 309-319
    • Simonet, W.S.1    Lacey, D.L.2    Dunstan, C.R.3
  • 4
    • 57249094356 scopus 로고    scopus 로고
    • Pathophysiological roles of osteoprotegerin (OPG)
    • COI: 1:CAS:528:DC%2BD1MXhvFGhu7w%3D, PID: 18707795
    • Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88(1):1–17.
    • (2009) Eur J Cell Biol , vol.88 , Issue.1 , pp. 1-17
    • Reid, P.1    Holen, I.2
  • 5
    • 0037086077 scopus 로고    scopus 로고
    • Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells
    • COI: 1:CAS:528:DC%2BD38XisVSisLw%3D, PID: 11912131
    • Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62(6):1619–23.
    • (2002) Cancer Res , vol.62 , Issue.6 , pp. 1619-1623
    • Holen, I.1    Croucher, P.I.2    Hamdy, F.C.3    Eaton, C.L.4
  • 6
    • 4043138669 scopus 로고    scopus 로고
    • Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis
    • COI: 1:CAS:528:DC%2BD2cXmt1Kqtro%3D, PID: 15567943
    • Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86(3):269–79.
    • (2004) Breast Cancer Res Treat , vol.86 , Issue.3 , pp. 269-279
    • Neville-Webbe, H.L.1    Cross, N.A.2    Eaton, C.L.3
  • 7
    • 0037374460 scopus 로고    scopus 로고
    • Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells
    • COI: 1:CAS:528:DC%2BD3sXhs1agtb0%3D, PID: 12615702
    • Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63(5):912–6.
    • (2003) Cancer Res , vol.63 , Issue.5 , pp. 912-916
    • Shipman, C.M.1    Croucher, P.I.2
  • 8
    • 24644435593 scopus 로고    scopus 로고
    • Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival?
    • COI: 1:CAS:528:DC%2BD2MXpvV2gs7c%3D, PID: 16155791
    • Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207–15.
    • (2005) Breast Cancer Res Treat , vol.92 , Issue.3 , pp. 207-215
    • Holen, I.1    Cross, S.S.2    Neville-Webbe, H.L.3
  • 9
    • 33645221176 scopus 로고    scopus 로고
    • Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
    • COI: 1:CAS:528:DC%2BD28Xjt1Gqtbw%3D, PID: 16287088
    • Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118(8):1901–8.
    • (2006) Int J Cancer , vol.118 , Issue.8 , pp. 1901-1908
    • Cross, S.S.1    Yang, Z.2    Brown, N.J.3
  • 10
    • 79953323463 scopus 로고    scopus 로고
    • Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties
    • COI: 1:CAS:528:DC%2BC3MXnt1ensrw%3D, PID: 21255246
    • Benslimane-Ahmim Z, Heymann D, Dizier B, et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost. 2011;9(4):834–43.
    • (2011) J Thromb Haemost , vol.9 , Issue.4 , pp. 834-843
    • Benslimane-Ahmim, Z.1    Heymann, D.2    Dizier, B.3
  • 11
    • 13344285339 scopus 로고
    • Identification and characterization of a new member of the TNF family that induces apoptosis
    • COI: 1:CAS:528:DyaK28XhtF2iug%3D%3D
    • Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immun. 1995;3(6):673–82.
    • (1995) Immun , vol.3 , Issue.6 , pp. 673-682
    • Wiley, S.R.1    Schooley, K.2    Smolak, P.J.3
  • 12
    • 17544367410 scopus 로고    scopus 로고
    • Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
    • COI: 1:CAS:528:DyaK28XjtlGjtrc%3D, PID: 8663110
    • Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687–90.
    • (1996) J Biol Chem , vol.271 , Issue.22 , pp. 12687-12690
    • Pitti, R.M.1    Marsters, S.A.2    Ruppert, S.3    Donahue, C.J.4    Moore, A.5    Ashkenazi, A.6
  • 13
    • 78149284013 scopus 로고    scopus 로고
    • Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
    • COI: 1:CAS:528:DC%2BC3cXht1ajtbvI, PID: 20881962
    • Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102.
    • (2010) Nature , vol.468 , Issue.7320 , pp. 98-102
    • Schramek, D.1    Leibbrandt, A.2    Sigl, V.3
  • 14
    • 78149284767 scopus 로고    scopus 로고
    • RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
    • COI: 1:CAS:528:DC%2BC3cXht1ajur7J, PID: 20881963
    • Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–7.
    • (2010) Nature , vol.468 , Issue.7320 , pp. 103-107
    • Gonzalez-Suarez, E.1    Jacob, A.P.2    Jones, J.3
  • 15
    • 79952193038 scopus 로고    scopus 로고
    • Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
    • COI: 1:CAS:528:DC%2BC3MXhvFKltL8%3D, PID: 21326202
    • Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–53.
    • (2011) Nature , vol.470 , Issue.7335 , pp. 548-553
    • Tan, W.1    Zhang, W.2    Strasner, A.3
  • 16
    • 79953305288 scopus 로고    scopus 로고
    • Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study
    • COI: 1:CAS:528:DC%2BC3MXnt1egurw%3D, PID: 21284802
    • Vik A, Mathiesen EB, Brox J, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost. 2011;9(4):638–44.
    • (2011) J Thromb Haemost , vol.9 , Issue.4 , pp. 638-644
    • Vik, A.1    Mathiesen, E.B.2    Brox, J.3
  • 17
    • 77953774003 scopus 로고    scopus 로고
    • Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population—the Tromso study
    • COI: 1:CAS:528:DC%2BC3cXnsVegtLk%3D, PID: 20128863
    • Vik A, Mathiesen EB, Johnsen SH, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population—the Tromso study. J Thromb Haemost. 2010;8(5):898–905.
    • (2010) J Thromb Haemost , vol.8 , Issue.5 , pp. 898-905
    • Vik, A.1    Mathiesen, E.B.2    Johnsen, S.H.3
  • 18
    • 61449257635 scopus 로고    scopus 로고
    • Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness
    • PID: 19091545
    • Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.
    • (2009) Eur J Cancer , vol.45 , Issue.7 , pp. 1218-1231
    • Larsen, I.K.1    Småstuen, M.2    Johannesen, T.B.3
  • 19
    • 2442492972 scopus 로고    scopus 로고
    • Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease
    • COI: 1:CAS:528:DC%2BD2cXjs1eisrk%3D, PID: 15117849
    • Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175–80.
    • (2004) Circulation , vol.109 , Issue.18 , pp. 2175-2180
    • Kiechl, S.1    Schett, G.2    Wenning, G.3
  • 20
    • 72049092419 scopus 로고    scopus 로고
    • Denosumab, Osteoporosis, and prevention of fractures
    • COI: 1:CAS:528:DC%2BD1MXhsFWgs7fI, PID: 19940304
    • Kiechl S, Willeit J, Schett G, et al. Denosumab, Osteoporosis, and prevention of fractures. N Engl J Med. 2009;361(22):2188–91.
    • (2009) N Engl J Med , vol.361 , Issue.22 , pp. 2188-2191
    • Kiechl, S.1    Willeit, J.2    Schett, G.3
  • 21
    • 0041854146 scopus 로고    scopus 로고
    • Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma
    • COI: 1:CAS:528:DC%2BD3sXmsVSitbY%3D, PID: 12838418
    • Ito R, Nakayama H, Yoshida K, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 2003;443(2):146–51.
    • (2003) Virchows Arch , vol.443 , Issue.2 , pp. 146-151
    • Ito, R.1    Nakayama, H.2    Yoshida, K.3
  • 22
    • 27944448767 scopus 로고    scopus 로고
    • Osteoprotegerin is expressed in colon carcinoma cells
    • COI: 1:CAS:528:DC%2BD2MXht12itrnM, PID: 16309167
    • Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25(6B):3809–16.
    • (2005) Anticancer Res , vol.25 , Issue.6B , pp. 3809-3816
    • Pettersen, I.1    Bakkelund, W.2    Smedsrød, B.3    Sveinbjørnsson, B.4
  • 23
    • 51049114701 scopus 로고    scopus 로고
    • OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer
    • PID: 18676739
    • De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 2008;14(15):4713–8.
    • (2008) Clin Cancer Res , vol.14 , Issue.15 , pp. 4713-4718
    • De Toni, E.N.1    Thieme, S.E.2    Herbst, A.3
  • 24
    • 0035992402 scopus 로고    scopus 로고
    • Serum osteoprotegerin levels in healthy controls and cancer patients
    • COI: 1:CAS:528:DC%2BD38XmtVWhsLY%3D, PID: 12114435
    • Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2002;8(7):2306–10.
    • (2002) Clin Cancer Res , vol.8 , Issue.7 , pp. 2306-2310
    • Lipton, A.1    Ali, S.M.2    Leitzel, K.3
  • 25
    • 79954608597 scopus 로고    scopus 로고
    • Clinical significance of osteoprotegerin expression in human colorectal cancer
    • COI: 1:CAS:528:DC%2BC3MXkslCgt78%3D, PID: 21270110
    • Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011;17(8):2444–50.
    • (2011) Clin Cancer Res , vol.17 , Issue.8 , pp. 2444-2450
    • Tsukamoto, S.1    Ishikawa, T.2    Iida, S.3
  • 26
    • 84866543321 scopus 로고    scopus 로고
    • RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model
    • COI: 1:CAS:528:DC%2BC38XhtlGmtr7N, PID: 22926264
    • Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat. 2012;135(3):771–80.
    • (2012) Breast Cancer Res Treat , vol.135 , Issue.3 , pp. 771-780
    • Canon, J.1    Bryant, R.2    Roudier, M.3    Branstetter, D.G.4    Dougall, W.C.5
  • 27
    • 79955772442 scopus 로고    scopus 로고
    • Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
    • COI: 1:CAS:528:DC%2BC3MXlslGmt7Y%3D, PID: 21559440
    • Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE. 2011;6(4):e19234.
    • (2011) PLoS ONE , vol.6 , Issue.4 , pp. e19234
    • Santini, D.1    Schiavon, G.2    Vincenzi, B.3
  • 28
    • 80052773257 scopus 로고    scopus 로고
    • Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis
    • Kamiya N, Suzuki H, Endo T, et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol. 2011;16(4):366–72.
    • (2011) Int J Clin Oncol , vol.16 , Issue.4 , pp. 336-372
    • Kamiya, N.1    Suzuki, H.2    Endo, T.3
  • 29
    • 84874883241 scopus 로고    scopus 로고
    • Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer
    • COI: 1:CAS:528:DC%2BC3sXks1WgsrY%3D, PID: 23516466
    • Peng X, Guo W, Ren T, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS ONE. 2013;8(3):e58361.
    • (2013) PLoS ONE , vol.8 , Issue.3 , pp. e58361
    • Peng, X.1    Guo, W.2    Ren, T.3
  • 30
    • 14844288360 scopus 로고    scopus 로고
    • Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
    • Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updates. 2004;7(6):345–58.
    • (2004) Drug Resist Updates , vol.7 , Issue.6 , pp. 345-358
    • Van Geelen, C.M.1    de Vries, E.G.2    de Jong, S.3
  • 31
    • 84868131986 scopus 로고    scopus 로고
    • Osteoprotegerin in bone metastases: mathematical solution to the puzzle
    • COI: 1:CAS:528:DC%2BC38Xhs1ansbfJ, PID: 23093918
    • Ryser MD, Qu Y, Komarova SV. Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol. 2012;8(10):e1002703.
    • (2012) PLoS Comput Biol , vol.8 , Issue.10 , pp. e1002703
    • Ryser, M.D.1    Qu, Y.2    Komarova, S.V.3
  • 32
    • 34447512931 scopus 로고    scopus 로고
    • Heparin induces mobilization of osteoprotegerin into the circulation
    • COI: 1:CAS:528:DC%2BD2sXotVyqsbk%3D, PID: 17598007
    • Vik A, Brodin E, Sveinbjornsson B, Hansen JB. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost. 2007;98(1):148–54.
    • (2007) Thromb Haemost , vol.98 , Issue.1 , pp. 148-154
    • Vik, A.1    Brodin, E.2    Sveinbjornsson, B.3    Hansen, J.B.4
  • 33
    • 34547574967 scopus 로고    scopus 로고
    • Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease
    • COI: 1:CAS:528:DC%2BD2sXnslKksLc%3D, PID: 17620507
    • Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116(4):385–91.
    • (2007) Circulation , vol.116 , Issue.4 , pp. 385-391
    • Kiechl, S.1    Schett, G.2    Schwaiger, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.